While infections pose a risk for morbidity and mortality among patients with MDS, more needs to be studied about the topic, ...

I bought 14 precious cancer bracelets in a discount store to help spread awareness about cancer — something I’m ready to ...

Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit ...

Among patients with myelodysplastic syndromes (MDS), treatment with Reblozyl (luspatercept) resulted in at least 12 weeks of ...

Trodelvy in locally advanced or metastatic urothelial cancer may provide another option for those whose disease progressed ...

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...

The past 15 months have been challenging regarding treatment for my ovarian cancer. But today, my goal is to focus on healing ...

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on ...

Vonjo was also shown to improve overall survival in patients with myelofibrosis treated with Vonjo in the real-world setting.

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a ...

I am still struggling to navigate the intrusive questions of well-meaning strangers 17 years after surviving inflammatory ...

Imfinzi with monalizumab and ceralasertib showed promising long-term benefits in advanced NSCLC, but no other combinations ...